Cancer treatment and research
Papers 2568
1 page of 257 pages (2,568 results)
#1S.M. Bollard (Mater Misericordiae University Hospital)
#2Cristina Casalou (UCD: University College Dublin)H-Index: 11
Last. S.M. Potter (Mater Misericordiae University Hospital)
view all 0 authors...
The treatment of Melanoma, one of the most aggressive human malignancies, has been revolutionised by the advent of novel targeted and immuno-therapies. However, methods utilised to detect early presentations, and to stratify risk for patients diagnosed with invasive melanoma in the clinical setting are lagging. The primary prognostic indicator is restricted to Breslow Thickness, or depth the tumour invades into the dermis. Gene Expression Profiling (GEP), the analysis of molecular gene signature...
#1Takashi Yamamichi (JFCR: Japanese Foundation for Cancer Research)
#2Masayuki Nakao (JFCR: Japanese Foundation for Cancer Research)H-Index: 11
Last. Mingyon Mun (JFCR: Japanese Foundation for Cancer Research)H-Index: 14
view all 0 authors...
OBJECTIVE The coexistence of interstitial lung disease (ILD) is associated with poor prognosis in patients with lung cancer. The tumor doubling time (TDT) of lung cancer reflects cancer aggressiveness and is related to its prognosis. However, the relationship between the TDT of lung cancer and underlying ILD has not been fully evaluated. This study aimed to identify this crucial relationship. MATERIALS AND METHODS Patients with lung cancer who underwent surgery between 2007 and 2020 were reviewe...
#1Catherine Hanna (Glas.: University of Glasgow)H-Index: 7
#2Kathleen A Boyd (Glas.: University of Glasgow)H-Index: 14
Last. Richard Wilson (Beatson West of Scotland Cancer Centre)
view all 0 authors...
Introduction null Over half of the 1.5 million individuals globally who are diagnosed with colorectal cancer (CRC) present with stage II-III disease. Understanding clinician attitudes towards treatment for this group is paramount to contextualise real-world outcomes and plan future trials. The aim of this study was to assess clinician awareness of trials assessing the optimal duration of CRC adjuvant therapy, their attitudes towards shorter treatment and their self-reported practice. null Method...
#1Davide MauriH-Index: 26
#2Spyridon TsiourisH-Index: 14
Last. Andreas FotopoulosH-Index: 23
view all 0 authors...
Immuno-oncology (IO) with immune checkpoint inhibitors (ICIs) is the new landmark in cancer treatment. However, due to its economical-related burden and the possibility of tumor pseudoprogression with late response patterns, it is imperative to find new ways for early discrimination of patients with IO-sensitive versus IO-resistant disease. ICI-mediated antitumor responses depend on tumor immune infiltration by T-cells capable of recognizing and killing tumor cells. Nevertheless, patients may ex...
#1G. Arrichiello (Seconda Università degli Studi di Napoli)H-Index: 1
#2L. Poliero (Seconda Università degli Studi di Napoli)H-Index: 2
Last. Erika MartinelliH-Index: 41
view all 9 authors...
Abstract null null Immunotherapy has recently become a major treatment modality for several types of solid tumours, achieving remarkable and long-lasting remissions. In metastatic colorectal cancer patients (mCRC), immune checkpoint inhibitors (ICIs) were found to be effective as treatment for deficient mismatch repair (dMMR)/ microsatellite instability high (MSI-H) tumours and received regulatory approval for this indication. However, mCRC is a complex disease and dMMR/MSI-H tumours represent a...
#1Anne C. Melzer (UMN: University of Minnesota)H-Index: 7
#2Abbie Begnaud (UMN: University of Minnesota)H-Index: 8
Last. Anne M. Joseph (UMN: University of Minnesota)H-Index: 34
view all 8 authors...
ONE CONCERN: as lung cancer screening (LCS) is implemented is that patients will be screened who are too ill to benefit. Poor exercise capacity (EC) predicts adverse outcomes following lung resection. OBJECTIVE Describe the distribution of EC among smokers eligible for LCS and examine associations with comorbidities. METHODS Cross-sectional analysis of baseline data from a randomized controlled trial of tobacco treatment in the context of LCS. Participants responded regarding limitations in mode...
#1Yutaka Takahara (Kanazawa Medical University)H-Index: 2
#2Keisuke Nakase (Kanazawa Medical University)H-Index: 1
Last. Shiro Mizuno (Kanazawa Medical University)H-Index: 22
view all 7 authors...
Objective null Lung cancer patients presenting with osteoblastic bone metastases at the first visit is rare. We investigated the clinical characteristics and gene mutation rate of non-small cell lung cancer patients with osteoblastic bone metastases at the time of the initial diagnosis. null Materials and methods null We retrospectively screened newly diagnosed non-small cell lung cancer patients with osteoblastic bone metastases who presented from June 2015 to March 2021, and analyzed their cli...
Top fields of study
Cancer research